Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Fig. 3

The genomic landscape of baseline RET fusion-positive patients. a Distribution of genetic alterations associated with baseline RET+ patients (N = 380). The distribution of somatic mutations (top) and CNVs (bottom) in baseline patients were assessed by targeted NGS. Each column represents one patient. Clinical characteristics of baseline RET+ patients are shown at the top. The frequency of each gene alteration is listed on the right. b Top frequently mutated gene alterations identified in RET + baseline patients. *P < 0.05, **P < 0.01, ***P < 0.001. c The correlation between signaling pathways in which the concurrent mutations occur and different types of RET fusions. The bar graph illustrates the proportion of baseline RET fusion-positive patients harboring genetic alterations in the relevant pathways. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page